iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage
biopharmaceutical company pioneering the discovery and development
of a new generation of highly differentiated immuno-oncology
therapeutics for patients, today announced the presentation of new
preclinical data for its anti-TIGIT monoclonal antibody, EOS-448,
at the 63rd American Society of Hematology (ASH) Annual Meeting
& Exposition and the TIGIT Therapies Digital Summit 2021.
“The data we presented this week at the TIGIT Therapies Digital
Summit provide further evidence of the multifaceted mechanism of
our high affinity, potent anti-TIGIT monoclonal antibody, EOS-448.
We presented preclinical data showing activation of immune
stimulatory cells is dependent on activating via FcγR, and also
show clinically that this activation is translating to depletion of
immunosuppressive cells. Furthermore, the upcoming data
presentations at ASH demonstrate the synergistic effect of
combining an FcγR active anti-TIGIT antibody with an IMiD in a
preclinical model of multiple myeloma and provide strong rationale
for our ongoing Phase 1/2 trial in this difficult to treat cancer,”
said Michel Detheux, Ph.D., president and chief executive officer
of iTeos. “These results underscore our enthusiasm for EOS-448 as a
potential therapy capable of harnessing the immune system to help
improve outcomes for patients with advanced, aggressive cancers. We
look forward to progressing our clinical development plan in 2022
in both multiple myeloma and solid tumors with several
combinations.”
ASH 2021:
The Combination of Anti-Tigit and Lenalidomide Promotes
Synergistic Myeloma-Specific Immunity after ASCTPresented
by: Simone A. Minnie, Ph.D., Clinical Research Division, Fred
Hutchinson Cancer Research Center, Seattle, WAAbstract #:
154087
Preclinical data demonstrating the efficacy of a mouse surrogate
EOS-448 as a single agent and in combination with an
immunomodulatory imide drug (IMiD) in a preclinical model of
multiple myeloma was presented by our collaborator at the Fred
Hutchinson Cancer Research Center. The Fc-enabled anti-TIGIT
monoclonal antibody elicited effective control of multiple myeloma
disease progression, while an Fc-disabled version was inactive,
indicating the importance of engaging the FcγR. Furthermore, the
Fc-enabled anti-TIGIT antibody demonstrated synergistic activity
when combined with an IMiD, a class of drugs that has previously
shown clinical activity in multiple myeloma.
TIG-007: Study of EOS884448/GSK4428859A Alone, and in
Combination with Iberdomide with or without Dexamethasone, in
Participants with Relapsed or Refractory Multiple
MyelomaPresented by: Philippe Moreau, M.D., Hematology
Department, Nantes University Hospital, Nantes, FranceAbstract #:
152395
The presentation highlighted TIG-007, an ongoing open-label,
multicenter, dose-escalation/expansion Phase 1/2 trial evaluating
the safety, tolerability, and preliminary activity of EOS-448 as
monotherapy and in combination with Bristol Myers Squibb’s IMiD,
iberdomide, with or without dexamethasone, in adults with relapsed
or refractory multiple myeloma. The preclinical data presented from
the preclinical model of multiple myeloma provide a strong
rationale for combining TIGIT inhibition with immunomodulatory
drugs to prevent the progression of myeloma, and previous studies
have shown notable clinical activity and acceptable tolerability
with iberdomide in combination with dexamethasone or other
antimyeloma agents in heavily pre-treated patients with relapsed or
refractory multiple myeloma. The study aims to assess the
therapeutic opportunity of EOS-448 alone or in combination with
iberdomide, with or without dexamethasone to amplify
myeloma-specific T cell anti-tumor responses in patients with
difficult-to-treat relapsed or refractory multiple myeloma.
TIGIT Therapies Digital Summit 2021:
Targeting TIGIT: Which cell populations are modulated by
FcγR engagement?Presented by: Gregory Driessens, Ph.D.,
Senior Director, Project Head, iTeos Therapeutics
The presentation featured both preclinical and clinical evidence
for the multifaceted mechanism of action of EOS-448, including
activation of T cells, modulation of antigen-presenting cells and
depletion of regulatory T cells (Tregs) and terminally exhausted T
cells. Preclinical data demonstrated that FcγR engagement activated
professional antigen-presenting cells either alone or
synergistically with anti-PD1, both in the tumor and within the
tumor draining lymph node. This effect was only evident when using
a fully functional anti-TIGIT antibody, providing support for the
design of EOS-448 as an IgG1 antibody. An update on the
pharmacodynamic effect of EOS-448 in the blood of treated patients
from the Phase 1 trial showed strong depletion of Tregs, an
increase in the CD8/Treg ratio and a transient increase in
proliferation (as assessed by the Ki67 marker), in line with
previous observations with pembrolizumab.
About iTeos Therapeutics, Inc.iTeos
Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery and development of a new generation of
highly differentiated immuno-oncology therapeutics for patients.
iTeos Therapeutics leverages its deep understanding of tumor
immunology and immunosuppressive pathways to design novel product
candidates with the potential to fully restore the immune response
against cancer. The Company’s innovative pipeline includes two
clinical-stage programs targeting novel, validated immuno-oncology
pathways designed with optimized pharmacologic properties for
improved clinical outcomes. The first antibody product candidate,
EOS-448, is a high affinity, potent, anti-TIGIT antibody with a
functional Fc domain, designed to enhance the anti-tumor response
through a multifaceted immune modulatory mechanism, currently
progressing in multiple indications in collaboration with GSK. The
Company is also advancing inupadenant, a next-generation adenosine
A2A receptor antagonist tailored to overcome cancer
immunosuppression into proof-of concept trials in several
indications following encouraging single-agent activity in Phase 1.
iTeos Therapeutics is headquartered in Cambridge, MA with a
research center in Gosselies, Belgium.
Internet Posting of InformationiTeos routinely
posts information that may be important to investors in the
'Investors' section of its website at www.iteostherapeutics.com.
The company encourages investors and potential investors to consult
our website regularly for important information about iTeos.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995 and other federal
securities laws. Any statements that are not statements of
historical fact may be deemed to be forward-looking statements.
Words such as “believe,” “anticipate,” “plan,” “expect,” “will,”
“may,” “intend,” “prepare,” “look,” “potential,” “possible” and
similar expressions are intended to identify forward-looking
statements. These forward-looking statements include statements
relating to the potential benefits of our product candidates,
including EOS-448’s potential to harness the immune system to help
improve outcomes for patients with advanced and aggressive cancers,
and our plan to progress our EOS-448 clinical development plan in
2022 in both multiple myeloma and solid tumors with several
combinations.
These forward-looking statements involve risks and
uncertainties, many of which are beyond iTeos’ control. Actual
results could materially differ from those stated or implied by
these forward-looking statements as a result of such risks and
uncertainties. Known risk factors include the following: success in
preclinical testing and early clinical trials does not ensure that
later clinical trials will be successful, and early results from a
clinical trial do not necessarily predict final results; the data
for our product candidates may not be sufficient for obtaining
regulatory approval; iTeos may not be able to execute on its
business plans, including meeting its expected or planned
regulatory milestones and timelines, research and clinical
development plans, and bringing its product candidates to market,
for various reasons, some of which may be outside of iTeos’
control, including possible limitations of company financial and
other resources, manufacturing limitations that may not be
anticipated or resolved for in a timely manner, regulatory, court
or agency decisions such as decisions by the United States Patent
and Trademark Office with respect to patents that cover our product
candidates and the impact of the COVID-19 pandemic; and those risks
identified under the heading “Risk Factors” in iTeos’s Quarterly
Report on Form 10-Q for the quarter ended September 30, 2021 filed
with the Securities and Exchange Commission (SEC) as well as other
SEC filings made by the Company which you are encouraged to
review.
Any of the foregoing risks could materially and adversely affect
iTeos’ business, results of operations and the trading price of
iTeos’ common stock. We caution investors not to place considerable
reliance on the forward-looking statements contained in this press
release. iTeos does not undertake any obligation to publicly update
its forward-looking statements based on events or circumstances
after the date hereof.
For further information, please contact:
Investor Contacts:Ryan BakeriTeos Therapeutics,
Inc.Ryan.Baker@iteostherapeutics.com
Media Contacts:media@iteostherapeutics.com
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
iTeos Therapeutics (NASDAQ:ITOS)
Historical Stock Chart
From Sep 2023 to Sep 2024